GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Median PS Value

Melodiol Global Health (ASX:ME1DE) Median PS Value : A$0.00 (As of Jun. 09, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Melodiol Global Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$4.032. Melodiol Global Health's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is A$0.00.

As of today (2024-06-09), Melodiol Global Health's share price is A$0.39. Melodiol Global Health's Median PS Value is A$0.00. Therefore, Melodiol Global Health's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Melodiol Global Health's Median PS Value or its related term are showing as below:

ASX:ME1DE's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.81
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Melodiol Global Health Median PS Value Historical Data

The historical data trend for Melodiol Global Health's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Median PS Value Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Melodiol Global Health's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Melodiol Global Health's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Price-to-Median-PS-Value falls into.



Melodiol Global Health Median PS Value Calculation

Melodiol Global Health's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.032*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Melodiol Global Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$4.032.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health  (ASX:ME1DE) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Melodiol Global Health's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.39/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health Median PS Value Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DE) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines